Developments in the Biotech and Pain Management Therapeutics Segments

NEW YORK, January 5, 2018 /PRNewswire/ --

According to a report by Grand View Research, Inc. the global biotechnology market is expected to reach USD 727.1 billion by 2025. Major technological advancements in segments such as regenerative medicine and genetics in diagnostics are important drives for the future of biotechnology. Innovative companies in the industry are engaged in large clinical trials and strong R&D investments for cancer therapeutics, as oncology is one of the most promising areas of focus in the biotech industry. Another large segment of the market is pain management therapeutics. Transparency Market Research indicates that the global market for pain management therapeutics has a high degree of competition, and is witnessing a continual entry of new companies owing to the high growth prospects. In terms of type of therapeutics, opioids and NSAIDS are the leading segments that account for key shares in the pain management therapeutics market. BioCorRx Inc. (OTC: BICX), Curis, Inc. (NASDAQ: CRIS), DURECT Corporation (NASDAQ: DRRX), Egalet Corporation (NASDAQ: EGLT), Trevena, Inc. (NASDAQ: TRVN).

Opioids are the most widely prescribed medications or the treatment of chronic pain conditions. A report by Transparency Market Research explains that these analgesics are used to manage pain in cancer patients and also to treat severe constant pain in patients suffering from terminal illnesses. Opioids are also a major cause of drug overdoses. The New York Times reported data provided by the CDC, according to which Drug overdoses killed roughly 64,000 people in the United States in 2016. A very strong increase of more than 22 percent from the previous year. According to the Times, "Drug overdoses are expected to remain the leading cause of death for Americans under 50, as synthetic opioids - primarily fentanyl and its analogues - continue to push the death count higher."

BioCorRx Inc. (OTCQB: BICX) recently announced breaking news that the Company's BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, was featured on CBC affiliate WBNS-10TV news in Ohio. The program features an individual suffering from opioid use disorder who has turned his life around since starting the BioCorRx Recovery Program. Participation in the Company's program was accepted in lieu of conviction by a Richland County judge in Ohio.

A link to the news story is available at: https://www.10tv.com/article/hi-tech-treatment-now-possible-opiate-addiction. After the segment aired, an update of the cost for treatment was posted in the written article associated with the video. The cost mentioned is the national average for the entire outpatient program that varies by each independent location and also typically includes medical follow-ups, cognitive behavioral therapy (CBT) with a licensed therapist for approximately 3 months and an overlapping peer recovery support and patient outcome tracking for one full year. In some cases, it may even include outpatient detox.

Brady Granier, CEO, President, and Director of BioCorRx, commented, "It's great to see our program featured in Ohio, one of the states most devastated by the opioid epidemic. More importantly, it's emotionally rewarding to see people get on their journey to recovery with our program. We are also honored that our program was approved to be utilized as treatment in lieu of conviction. We hope to see more of this in the future as it can help people get well and on the road to recovery, while also reducing the financial burden of incarceration on society."

About BioCorRx - is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit http://www.BioCorRx.com. "

Curis, Inc. (NASDAQ: CRIS) is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. On November 7, 2017, the company reported its financial results for the third quarter ended September 30, 2017. Revenues for the third quarter of 2017 were $2.4 million, as compared to $1.8 million for the same period in 2016. Revenues for the nine months ended September 30, 2017 were $6.6 million, as compared to $5.2 million for the same period in 2016. Revenues for both periods comprise primarily royalty revenues recorded on Genentech and Roche's net sales of Erivedge®.

DURECT Corporation (NASDAQ: DRRX) is a biopharmaceutical company actively developing new therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms. DURECT's advanced oral, injectable, and transdermal delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIR® (SABER®-Bupivacaine), an investigational locally-acting, non-opioid analgesic intended to provide up to 3 days of continuous pain relief after surgery. On December 13, 2017, the company announced that Indivior PLC has reported that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for RBP-7000. RBP-7000 is an investigational, once-monthly injectable risperidone for the treatment of schizophrenia. Indivior PLC further reported that the FDA has set a PDUFA (Prescription Drug User Fee Act) target action date of July 28, 2018.

Egalet Corporation (NASDAQ: EGLT), a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Using Guardian Technology, Egalet is developing a pipeline of clinical-stage, product candidates for which we are seeking partners including Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Recently, the company announced that it has partnered with OraPharma, Inc., a division of Valeant Pharmaceuticals International, Inc., to co-promote SPRIX (ketorolac tromethamine) Nasal Spray to dentists, dental specialists and oral surgeons across the United States. SPRIX Nasal Spray is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the short-term (up to five days in adults) management of moderate to moderately severe pain that requires analgesia at the opioid level.

Trevena, Inc. (NASDAQ: TRVN) is a biopharmaceutical company focused on providing better, safer therapies to patients in pain. Recently, the company announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for OLINVO™ (oliceridine) Injection. The Company expects that the PDUFA date for the NDA will be in the fourth quarter of 2018. OLINVO is an investigational product for the management of moderate to severe acute pain.  It is the first G protein biased ligand of the mu receptor designed to provide IV opioid pain relief with fewer associated adverse effects.

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. FinancialBuzz.com has not been compensated. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news dissemination and PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com.

For further information:
Media Contact:
[email protected]
+1-877-601-1879

URL: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com